GE Healthcare aims to end unpredictability in early drug research
This article was originally published in Scrip
Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of reliable stem cell lines is just around the corner, head of cell technologies R&D Dr Stephen Minger tells Ashley Yeo.
You may also be interested in...
This week's Device Week podcast covers recent regulatory developments in Asia in the wake of COVID-19, and how regulators are adjusting to working under the pandemic. Having published two updates from our regular Asian Medtech Associations Reg Networking discussions this week, Medtech Insight speaks to Asia Regulatory Professional Association founder Jack Wong on Asian regulatory themes and South Korea's hosting of the next International Medical Device School.
Asian Medtech Associations Reg Networking: ASEANMed Drives Medtech Agenda Forward Despite COVID-19 – Part Two
The Asian Medtech Associations Regulatory Networking discussions this month centered on strategies to control COVID-19 locally and the activities of the ASEANMed industry association. This editorial feature is hosted by Medtech Insight, along with the ARQon Asia Regulatory and Quality Consultancy and the Asia Regulatory Professional Association. This is the second of two articles on the discussions.
ResMed’s respiratory device portfolio has put it front and center of the global medtech industry’s efforts to bring COVID-19 under control. UK and Ireland country manager Antoine Valterio tells In Vivo how the company rose to the challenge, and how providers are now seeing digital technologies in a new light.